A study examining ancient mummies from various countries revealed that one-third of them had atherosclerosis (plaques in the arteries), a precursor to heart disease, regardless of following Paleo-type or Mediterranean-type diets. This ratio mirrors what we see in modern populations. Listen in this week as Dee uncovers how we can harness the power of diet to overcome our genetic predispositions and lead healthier, heart-friendly lives.

Reference:

Thompson, R. C., Allam, A. H., Lombardi, G. P., Wann, L. S., Sutherland, M. L., Sutherland, J. D., Soliman, M. A.-T., Frohlich, B., Mininberg, D. T., Monge, J. M., Vallodolid, C. M., Cox, S. L., Abd el-Maksoud, G., Badr, I., Miyamoto, M. I., el-Halim Nur el-din, A., Narula, J., Finch, C. E., & Thomas, G. S. (2013). Atherosclerosis across 4000 years of human history: The horus study of four ancient populations. The Lancet, 381(9873), 1211–1222. https://doi.org/10.1016/s0140-6736(13)60598-x

A new study shows that a high-fat diet suppresses the expression of a protein called Jak3, which causes a cascade of inflammation that starts in the intestine, moves through the liver and on to the brain, ultimately causing Alzheimer's-like symptoms. Listen in this week as Dee discusses the results of this study and what it means for your health.

References:

Kumar, N., Mishra, J., Morales, R., & Kumar, P. (2024). Kinases in Gut-Liver-brain communication and neuroinflammation. Journal of Biological Chemistry, 300(3), 106750. https://www.jbc.org/article/S0021-9258(24)01223-7/fulltext

Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in the intestines during meals. It helps regulate blood sugar and weight by increasing insulin, slowing stomach emptying, and promoting fullness. Medications like Ozempic® and Wegovy® mimic the effects of GLP-1 but can be expensive and have unpleasant side effects. Listen in this week as Dee explores research on foods and probiotics that naturally boost GLP-1, offering similar benefits without the high costs and side effects.

References:

De Silva, A., & Bloom, S. R. (2012). Gut hormones and appetite control: A focus on PYY and GLP-1 as therapeutic targets in obesity. Gut and Liver, 6(1), 10–20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286726/

Hira, T., Trakooncharoenvit, A., Taguchi, H.;,Hara, H. (2021). Improvement of glucose tolerance by food factors having glucagon-like peptide-1 releasing activity. International Journal of Molecular Sciences, 22(12), 6623. https://www.mdpi.com/1422-0067/22/12/6623

Perraudeau, F., McMurdie, P., Bullard, J., Cheng, A., Cutcliffe, C., Deo, A., Eid, J., Gines, J., Iyer, M., Justice, N., Loo, W. T., Nemchek, M., Schicklberger, M., Souza, M., Stoneburner, B., Tyagi, S., & Kolterman, O. (2020). Improvements to postprandial glucose control in subjects with type 2 diabetes: A multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Research and Care, 8(1), e001319. https://drc.bmj.com/content/8/1/e001319

Link to purchase GLP-1 Probiotic: https://pendulumlife.com/products/glp-1-probiotic